Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) announced a definitive agreement for Lilly to acquire Mor...
Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced that Boehringer wi...
Johnson & Johnson announced positive results from the nipocalimab Phase 3 Vivacity-MG study in patients with generalized myasthenia gravis (gMG...
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today anno...
The PPD clinical research business will nearly double its laboratory footprint in northern Kentucky, add more than 250 jobs The PPD clinical research bu...
SNIPR Biome, a pioneer in the development CRISPR-Cas armed phages (CAPs) to prevent and treat bacterial infections, announced today that it has received ...
Novo Nordisk announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK...
The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with A...
EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients NDO is a severe bladder condition affecting millions of ...
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47...
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, unveiled a new clinical research laboratory build...
Labcorp a global leader of innovative and comprehensive laboratory services, announced the launch of Labcorp Global Trial Connect, a suite of...
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is embracing the theme of the 60th annual Drug ...
Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE®(acalabrutinib) in combination with bendamustine and rituximab de...
© 2025 Biopharma Boardroom. All Rights Reserved.
